The E test and the reference agar dilution methods were compared for detecting high-level aminoglycoside resistance (HLAR) Nosocomial infections caused by enterococci have been increasing in incidence during the last several years (3, 8, 10) to such an extent that enterococci are listed as the third most commonly isolated pathogen (4). Serious enterococcal sepsis involving bones or heart valves requires treatment with a combination of an aminoglycoside and a cell-wall active agent such as penicillin, aminopenicillins, or vancomycin (5). Unfortunately, increasing prevalence of high-level aminoglycoside resistance (HLAR) among clinical isolates of both Enterococcus faecalis and Enterococcus faecium has been more frequently reported (3, 6, 8, 9, 12 Table 1 . The MICs for 90% of the strains tested (MIC90s) for E. faecalis isolates were 2 ,ug/ml for both ampicillin and imipenem, confirming earlier studies of this species with Iso-Sensitest agar supplemented with 10% sheep blood (2) and the agar incorporation technique in Iso-Sensidisc agar (7). In contrast, Louie et al. (9) found slightly higher (2 to 4 ,ug/ml) ampicillin and imipenem MIC90s by the broth microdilution method. The E test MIC90 of penicillin and vancomycin was 3 ,g/ml for the E. faecalis strains. Vancomycin also showed a MIC9J of 3 ,ug/ml by the E test, modestly elevated compared with the results obtained on agar dilution tests (2, 7) but slightly lower (1 log2 dilution) than those produced by broth-based methods (9). Piperacillin had a MIC.E of 6 ,ug/ml (range, 2.0 to 12 jig/ml), which was considered a susceptible level.
The E test and the reference agar dilution methods were compared for detecting high-level aminoglycoside resistance (HLAR) among 71 selected clinical isolates, including 62 Enterococcus faecalis and 9 Enterococcus faecium isolates. High-level gentamicin resistance alone was found in 11% (5 E. faecalis and 3 E. faecium strains) and high-level streptomycin resistance was found in 42% (28 E. faecalis, 2 E. faecium strains) of the strains tested, and 31% of the strains demonstrated high-level resistance to both antimicrobial agents (21 E. faecalis and 1 E. faecium strains). The E test detected all HLAR populations, but the streptomycin strip may require recalibration to achieve absolute MIC comparisons with the reference value (twofold less) or the use of an alternative interpretive resistance breakpoint, e.g., > 1,000 IagIml. By the E test, MIC results indicate that ampicillin, imipenem, penicillin, piperacillin, and vancomycin remain active against the HLAR E. faecalis isolates; however, these tested drugs were less effective on the HLAR E. faecium isolates (<50%).
Nosocomial infections caused by enterococci have been increasing in incidence during the last several years (3, 8, 10) to such an extent that enterococci are listed as the third most commonly isolated pathogen (4) . Serious enterococcal sepsis involving bones or heart valves requires treatment with a combination of an aminoglycoside and a cell-wall active agent such as penicillin, aminopenicillins, or vancomycin (5). Unfortunately, increasing prevalence of high-level aminoglycoside resistance (HLAR) among clinical isolates of both Enterococcus faecalis and Enterococcus faecium has been more frequently reported (3, 6, 8, 9, 12) .
The E test (AB Biodisk, Solna, Sweden) is a new in vitro susceptibility testing method used for quantitative determination of susceptibility to antimicrobial agents (1) . E test technology is based on the diffusion of a defined continuous antimicrobial gradient from a thin plastic strip, producing an organism inhibition ellipse whose intercepts with the graded test carrier indicate MICs (1, 13 ,ug/ml). Imipenem was tested in a lower range, with MICs of 0.002 to 32 ,ug/ml. Gentamicin and streptomycin were tested with two high-MIC-range investigational strips each of 0.064 to 1,024 p,g/ml and 0.125 to 2,048 p,g/ml (usual range, 0.016 to 256 p,g/ml). The highest-range variety will be the marketed type. MICs were measured by the E test according to the manufacturer's package insert. Reagent-grade aminoglycoside powders were obtained from their domestic manufacturers and used in the reference agar (brain heart infusion agar) dilution MIC testing method according to procedures described by the National Committee for Clinical Laboratory Standards (11) .
A total of 71 enterococci consisting of 62 E. faecalis and 9 (2) and the agar incorporation technique in Iso-Sensidisc agar (7) . In contrast, Louie et al. (9) found slightly higher (2 to 4 ,ug/ml) ampicillin and imipenem MIC90s by the broth microdilution method. The E test MIC90 of penicillin and vancomycin was 3 ,g/ml for the E. faecalis strains. Vancomycin also showed a MIC9J of 3 ,ug/ml by the E test, modestly elevated compared with the results obtained on agar dilution tests (2, 7) but slightly lower (1 log2 dilution) than those produced by broth-based methods (9) . Piperacillin had a MIC.E of 6 ,ug/ml (range, 2.0 to 12 jig/ml), which was considered a susceptible level.
We found that some E. faecium isolates would be considered qualitatively resistant to all antimicrobial agents (except vancomycin) if the current interpretative criteria of the National Committee for Clinical Laboratory Standards for dilution susceptibility tests were applied to the E test results. These results contrast with those reported by others (2) for tests of E. faecium resistance to ampicillin and imipenem. The E test results demonstrated slightly greater susceptibility for E. faecium when vancomycin was tested (M1C50, 1.5 ,ug/ml) than for E. faecalis isolates.
In general, the aminoglycoside E test results (on scale for comparison) were lower (less than 1 log2 dilution) than those obtained by the reference agar dilution method. The correlation between the test MICs produced by agar dilution and the E test method for gentamicin is shown in Table 2 .
Isolated high-level gentamicin resistance (reference MIC, >500 ,ug/ml) was observed in 11% of the isolates. Five of (13) . Table 3 lists the results of the MICs for streptomycin obtained by the reference agar dilution method and the E test. High-level streptomycin resistance alone (MIC, >2,000 pg/ml) was detected in 42% of the isolates (28 E. faecalis and 2 E. faecium isolates). The E test clearly separated the two populations of streptomycin-resistant enterococci. The modal MIC for the population with high-level resistance was .2,048 ,ug/ml, but the MIC range was 1,024 to .2,048 ,ug/ml.
The isolates that were more streptomycin susceptible (MIC range, 96 to 384 p,g/ml), for which synergistic killing was demonstrated by streptomycin combined with selected cell wall-active drugs, were separated from potentially nonsyn- All 62 E. faecalis isolates were interpreted as resistant (11) when tested with amikacin E test strips (MIC., >256 ,ug/ml), and the MIC50 of amikacin for E. faecium strains was 192 ,ug/ml (data not shown).
In conclusion, the E test demonstrated its ability to assess the in vitro activities of various antienterococcal drugs of contemporary therapeutic significance (Table 1) . Further (Table 1) .
